<DOC>
	<DOCNO>NCT01549509</DOCNO>
	<brief_summary>The RV 156A clinical trial evaluate experimental HIV vaccine people infect HIV . Participants study randomly assign receive either HIV vaccine placebo . This study enroll people participate RV 156 study . In study , researcher evaluate safety immune response different experimental HIV vaccine people participate RV 156 study .</brief_summary>
	<brief_title>Evaluating Safety Immune Response HIV Vaccine Healthy , HIV-Uninfected Adults Uganda</brief_title>
	<detailed_description>RV 156A single site , phase 1 open label study accrual restrict participant RV 156 . Participants RV 156 study randomly assign receive three injection either placebo VRC-HIVDNA009-00-VP vaccine . All participant study receive one injection different experimental HIV vaccine , VRC-HIVADV014-00-VP . The purpose study evaluate safety immunogenicity VRC-HIVADV014-00-VP vaccine people participate RV 156 study . Researchers examine difference immune response VRC-HIVADV014-00-VP vaccine people receive placebo RV 156 study people receive VRC-HIVDNA009-00-VP vaccine RV 156 study . A projected number 29 volunteer enrol Makerere University site Uganda . At study entry , participant undergo physical examination , medical history review , vital sign measurement , blood urine collection . They also receive counsel HIV prevention pregnancy prevention . Participants receive one injection VRC-HIVADV014-00-VP vaccine upper arm . They remain clinic 30 45 minute observation monitoring . For 3 day vaccination , participant record temperature adverse symptom diary . Additional study visit occur Days 3 , 14 , 28 , 42 , 84 , 168 , 252 , 336 . At visit , participant undergo study procedure complete study entry visit .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>18 40 year old time RV 156 enrollment Available followup duration study ( 13 month ) Satisfactory completion Assessment Understanding prior enrollment , define 90 % correct three opportunity take test Able willing sign inform consent form Willing receive HIV counsel test accordance Ugandan Ministry Health guideline Willing engage highrisk behavior HIV infection study define protocol amenable riskreduction counsel discussion HIV infection risk In good general health Physical examination laboratory result without clinically significant finding within 45 day prior rAd5 boost injection Have participate RV 156 receive three require vaccination Laboratory Criteria within 45 day prior enrollment : Hemoglobin great 11.0 g/dL woman 12.5 g/dL men accompany site physician approval site 's low limit normal ( LLN ) range White blood cell count ( WBC ) 3,300 12,000 cells/mm^3 ( absence clinical pathological etiology ) Absolute neutrophil count ( ANC ) within institutional normal range great equal 1,000 cells/mm^3 accompany site physician approval Total lymphocyte count great 800 cells/mm^3 Platelets equal 125,000 550,000 cells/mm^3 Alanine aminotransferase ( ALT ) ( serum glutamic pyruvic transaminase [ SGPT ] ) less 1.25 time upper limit normal ( ULN ) Serum creatinine less 1.0 time ULN range Normal urinalysis , define dipstick negative glucose , negative trace protein , negative trace hemoglobin ( blood ) determine clinically significant site principal investigator Negative serology HIV infection ( e.g. , enzyme link immunosorbent assay [ ELISA ] test , western blot [ WB ] ) HIV ribonucleic acid ( RNA ) detection limit Food Drug Administration ( FDA ) approve viral load diagnostic assay PregnancySpecific Criteria : Negative serumhuman chorionic gonadotropin ( HCG ) pregnancy test woman . A female participant must meet one follow criterion screen visit throughout duration study : 1 . No reproductive potential hysterectomy , bilateral oophorectomy , tubal ligation . Documentation qualify medical doctor must obtain confirmation procedure . OR 2 . Participant agree consistently practice contraception least 21 day prior vaccination throughout duration study ( 13 month ) . More information criterion find protocol Pregnant , breastfeeding , plan become pregnant period study participation Immunosuppressive cytotoxic medication within past 6 month exception corticosteroid nasal spray allergic rhinitis topical corticosteroid acute uncomplicated dermatitis Blood product within 120 day prior HIV screen Immunoglobulin within 60 day prior HIV screen Live attenuate vaccine within 30 day prior initial study vaccine administration Investigational research agent within 30 day prior initial study vaccine administration Medically indicate subunit kill vaccine , e.g. , influenza , pneumococcal , allergy treatment antigen injection , within 14 day study vaccine administration Current antituberculosis ( TB ) prophylaxis therapy People history follow clinically significant condition exclude : Serious adverse reaction vaccine anaphylaxis , hive , respiratory difficulty , angioedema , abdominal pain Autoimmune disease immunodeficiency Asthma unstable require emergent care , urgent care , hospitalization , intubation past 2 year . Asthma require use oral intravenous corticosteroid past 2 year . Diabetes mellitus ( type I II ) , exception gestational diabetes Thyroid disease , include history thyroidectomy diagnose require medication within past 36 month Serious angioedema episode within previous 36 month require medication previous 2 year Hypertension well control medication blood pressure great equal 150/100 mm Hg ( either value ) second screen and/or entry visit Bleeding disorder diagnose doctor ( e.g. , factor deficiency , coagulopathy , platelet disorder require special precaution ) significant bruise bleed difficulty intramuscular ( IM ) injection blood draw Active syphilis document exam serology unless positive serology remote treat infection positive rapid plasma regain/venereal disease research laboratory ( RPR/VDRL ) test associate positive Treponemal specific serology Malignancy active , treated malignancy reasonable assurance sustain cure , malignancy likely recur period study Seizure disorder febrile seizures age 2 Asplenia splenic hypoplasia ( complete partial lack splenic function ) condition result absence functional spleen removal spleen Psychiatric condition precludes compliance protocol , past present psychosis , past present bipolar disorder , suicidal attempt Any medical , psychiatric , social condition , occupational responsibility , judgment investigator , would interfere serve contraindication protocol adherence person 's ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>